CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ:CERS) announced today that its fourth quarter
and year-end 2012 financial results will be released on Thursday,
February 28, 2013, after the close of the stock market. The company will
host a conference call and webcast at 4:15 PM ET that afternoon, during
which management will discuss the Company’s financial results and
provide a general business overview and outlook.
To access the live webcast, please visit the Investor Relations page of
the Cerus website at http://www.cerus.com/ir.
Alternatively, you may access the live conference call by dialing
866-235-9006 (U.S.) or 631-291-4549 (international).
A replay will be available on the company’s website, or by dialing
855-859-2056 (U.S.) or 404-537-3406 (international) and entering
conference ID number 96997633. The replay will be available
approximately three hours after the call through March 13, 2013.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused on
commercializing the INTERCEPT Blood System to enhance blood safety. The
INTERCEPT system is designed to reduce the risk of
transfusion-transmitted diseases by inactivating a broad range of
pathogens such as viruses, bacteria and parasites that may be present in
donated blood. The nucleic acid targeting mechanism of action enables
INTERCEPT treatment to inactivate established transfusion threats, such
as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed
to inactivate emerging pathogens such as influenza, malaria and
dengue. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in Europe, the Commonwealth of Independent
States, the Middle East and selected countries in other regions around
the world. In the United States, Cerus is seeking regulatory approval of
the INTERCEPT Blood System for plasma, and is in discussion with FDA to
define the additional clinical data required for a regulatory submission
for the INTERCEPT Blood System for platelets. The INTERCEPT Blood System
for red blood cells is in clinical development. See http://www.cerus.com for
more information.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
Source: Cerus Corporation